{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:01:12Z","timestamp":1761872472587,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["175:1298-1304"],"award-info":[{"award-number":["175:1298-1304"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:19:39Z","timestamp":1697282379000},"page":"e40-e49.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed\/Refractory Multiple Myeloma Outside of the Clinical Trial Setting"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuvan","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varga","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Ladicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawal","family":"Bent-Ennakhil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn Marie","family":"Stull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Gavini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.003_bib0001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.10.003_bib0002","unstructured":"Millennium Pharmaceuticals Inc. NINLARO\u00ae (ixazomib) capsules, for oral use. United States Prescribing Information; revised: April 2022. Accessed: June 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208462s012s013lbl.pdf."},{"key":"10.1016\/j.clml.2023.10.003_bib0003","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.10.003_bib0004","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","article-title":"Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.10.003_bib0005","unstructured":"Takeda Pharma A\/S. NINLARO: EPAR product information. summary of product characteristics; last updated: 05 September 2023. Accessed: June 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ninlaro-epar-product-information_en.pdf."},{"key":"10.1016\/j.clml.2023.10.003_bib0006","series-title":"Poster presented at EHA 2020; EP976","article-title":"Ixazomib-based therapy in relapsed\/refractory multiple myeloma (MM) patients (pts) treated via an early access program (EAP) in Europe: the \"use via early access to ixazomib\" (UVEA-IXA) study","author":"Ludwig","year":"2020"},{"key":"10.1016\/j.clml.2023.10.003_bib0007","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.10.003_bib0008","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00277-020-03985-9","article-title":"Ixazomib-based regimens for relapsed\/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study","volume":"99","author":"Cohen","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.10.003_bib0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12885-020-07732-1","article-title":"Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice","volume":"21","author":"Minarik","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2023.10.003_bib0010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s12253-019-00607-2","article-title":"Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed\/refractory multiple myeloma: data collected from the hungarian ixazomib named patient program","volume":"25","author":"Varga","year":"2019","journal-title":"Path Oncol Res"},{"key":"10.1016\/j.clml.2023.10.003_bib0011","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2217\/fon-2020-1225","article-title":"Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma","volume":"17","author":"H\u00e1jek","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2023.10.003_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-133807","article-title":"Real-life-setting effectiveness of ixazomib in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: the remix study","volume":"136","author":"Clement-Filliatre","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.003_bib0013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12185-022-03479-6","article-title":"Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and\/or refractory multiple myeloma","volume":"117","author":"Lee","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2023.10.003_bib0014","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.3390\/cancers14205165","article-title":"Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow-up analysis and the results of subsequent therapy","volume":"14","author":"Minarik","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.10.003_bib0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ejh.13586","article-title":"Outcomes of ixazomib\/lenalidomide\/dexamethasone for multiple myeloma: a multicenter retrospective analysis","volume":"106","author":"Takakuwa","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.10.003_bib0016","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2169\/internalmedicine.7768-21","article-title":"Safety profile of ixazomib in patients with relapsed\/refractory multiple myeloma in Japan: an all-case post-marketing surveillance","volume":"61","author":"Kakimoto","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.clml.2023.10.003_bib0017","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/blood-2021-150150","article-title":"The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): a pooled analysis of relapsed\/refractory multiple myeloma (RRMM) patients (pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice","volume":"138","author":"Leleu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.003_bib0018","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/PPA.S183187","article-title":"Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?","volume":"12","author":"Wilke","year":"2018","journal-title":"Patient Prefer Adher"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:49Z","timestamp":1761871429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023021481"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed\/Refractory Multiple Myeloma Outside of the Clinical Trial Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}